Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Issues Earnings Results, Beats Estimates By $0.08 EPS

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) released its quarterly earnings data on Tuesday. The company reported $0.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.08, Zacks reports. Swedish Orphan Biovitrum had a return on equity of 15.74% and a net margin of 1.43%.The business had revenue of $755.76 million during the quarter, compared to analyst estimates of $746.62 million.

Swedish Orphan Biovitrum Price Performance

Shares of Swedish Orphan Biovitrum stock opened at $43.15 on Thursday. The business’s fifty day moving average price is $40.10 and its two-hundred day moving average price is $37.04. The company has a debt-to-equity ratio of 0.14, a current ratio of 0.90 and a quick ratio of 0.59. The company has a market capitalization of $15.36 billion, a P/E ratio of 331.95 and a beta of 0.35. Swedish Orphan Biovitrum has a 1-year low of $27.06 and a 1-year high of $43.15.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on BIOVF shares. Barclays restated an “overweight” rating on shares of Swedish Orphan Biovitrum in a research report on Tuesday, February 24th. Danske downgraded Swedish Orphan Biovitrum to a “hold” rating in a research note on Thursday, February 19th. Finally, BNP Paribas Exane raised Swedish Orphan Biovitrum to an “outperform” rating in a research note on Tuesday, February 10th. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy”.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.